Assembly Biosciences Reported Phase 1a Trial Results
The company’s drug candidate showed potential for treating bile acid-related liver conditions.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies prioritize patient safety during the clinical testing of new drugs?
Assembly Biosciences completed a randomized, blinded Phase 1a clinical trial for ABI-6250, an experimental therapy for liver diseases. The company reported the drug was well-tolerated with no serious adverse events in healthy participants.
Why it matters
The study validates a mechanism targeting bile acid uptake, marking a step toward Phase 2 clinical trials for chronic hepatitis D virus (HDV) and other cholestatic liver diseases. These results help establish the safety profile required to advance the therapy toward larger efficacy trials.
ABI-6250 demonstrated dose-dependent, reversible increases in bile acids, confirming its activity in the target pathway. The pharmacodynamic data was recognized as a Poster of Distinction.
The players
Assembly Biosciences
A South San Francisco-based biotechnology firm focused on developing small-molecule therapeutics for viral infections and liver diseases.
The details
ABI-6250 functions by inhibiting the sodium taurocholate co-transporting polypeptide—a transport protein located on the surface of hepatocytes—which effectively blocks the uptake of bile acids into liver cells. By preventing this transport, the drug modulates bile acid circulation. This pharmacological process was studied for safety and tolerability in healthy subjects.
Timeline
November 5-9, 2026: The Liver Meeting 2026 takes place in Denver.
November 7, 2026: Clinical data from the Phase 1a study is scheduled for presentation.
Q4 2026: The company intends to begin Phase 2 trials for chronic HDV.
Q1 2027: The company intends to begin Phase 2 trials for cholestatic liver diseases.
The Tech Race
The development of sodium taurocholate co-transporting polypeptide inhibitors represents a competitive race to treat chronic liver infections and cholestatic conditions. Assembly Biosciences is now moving to position its candidate within the broader pipeline of next-generation hepatology treatments.
The drug is currently in the research stage and not available for clinical use. Patients and clinicians should monitor upcoming Phase 2 trial enrollment announcements for potential participation opportunities.
The takeaway
The successful Phase 1a trial provides the necessary safety data to move toward disease-specific efficacy testing. Observers should track the Q4 2026 start date for the planned Phase 2 trials to gauge the drug's performance in patient populations.
What happens next
Phase 2 studies for chronic HDV are planned for the fourth quarter of 2026, followed by trials for cholestatic liver diseases in the first quarter of 2027.
Further reading
For broader trends in liver therapy development, see the latest updates in Biotech.
Live Poll
Do you trust that pharmaceutical companies prioritize patient safety during the clinical testing of new drugs?
